# Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection

> **NCT04178850** · PHASE3 · UNKNOWN · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 568 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** GB242
- **BIOLOGICAL:** Infliximab

## Key facts

- **NCT ID:** NCT04178850
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-13
- **Primary completion:** 2020-12
- **Final completion:** 2021-04
- **Target enrollment:** 568 (ESTIMATED)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04178850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04178850, "Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04178850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*